June 1, 2020
Sumitomo Dainippon Pharma said on May 29 that it will merge two US subsidiaries Boston Biomedical and Tolero Pharmaceuticals into a single entity in a bid to boost efficiency in the group’s oncology R&D. Both subsidiaries conduct oncology R&D, with...read more